Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. (Q43209248)

16 November 2017

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. (English)

1 reference

16 November 2017

1 reference

10

Vincent Soriano

1 reference

16 November 2017

Eugenia Vispo

1

1 reference

16 November 2017

Alvaro Mena

2

1 reference

16 November 2017

Ivana Maida

3

1 reference

16 November 2017

Francisco Blanco

4

1 reference

16 November 2017

Mateo Cordoba

5

1 reference

16 November 2017

Pablo Labarga

6

1 reference

16 November 2017

Sonia Rodriguez-Novoa

7

1 reference

16 November 2017

Elena Alvarez

8

1 reference

16 November 2017

Inmaculada Jimenez-Nacher

9

1 reference

16 November 2017

language of work or name

English

0 references

publication date

23 December 2009

1 reference

Journal of Antimicrobial Chemotherapy

16 November 2017

1 reference

16 November 2017

65

1 reference

16 November 2017

3

1 reference

16 November 2017

543-547

1 reference

Raltegravir with optimized background therapy for resistant HIV-1 infection

16 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP446

21 January 2018

Identifiers

DOI

10.1093/JAC/DKP446

1 reference

16 November 2017

1 reference